BUREAU-VERITAS
22.2.2024 09:45:27 CET | Business Wire | Press release
Regulatory News:
2023 Key Figures1
- Revenue of EUR 5,867.8 million for the full year 2023, up 8.5% organically and up 3.8% on a reported basis (including a positive 0.6% scope effect and a negative 5.3% currency fluctuations)
- In the fourth quarter, organic revenue growth achieved 9.4%
- Adjusted operating profit of EUR 930.2 million, up 3.1% versus EUR 902.1 million in 2022, representing an adjusted operating margin of 15.9%, down c.10 basis points on a reported basis, and up 20 basis points organically at 16.2% (of which +c.50bps in H2 2023)
- Operating profit of EUR 824.4 million, up 3.1% versus EUR 799.3 million in 2022
- Attributable net profit of EUR 503.7 million, up 7.9% versus EUR 466.7 million in 2022
- Adjusted net profit of EUR 574.7 million (adjusted EPS of EUR 1.27 per share), up 7.6% versus EUR 533.9 million in 2022 and up 17.6% at constant currency
- Free cash flow of EUR 659.1 million (11% of Group revenue), up 0.3% year-on-year and 5.5% at constant currency, led by disciplined capex policy and working capital management
- Adjusted net debt/EBITDA ratio2 reduced to 0.92x as of December 31, 2023, versus 0.97x last year
- Proposed dividend of EUR 0.83 per share3, up 7.8% year-on-year, payable in cash
2023 Highlights
- Appointment of a new CEO and strengthening of the Executive Committee to support future growth ambitions
- 2023 financial targets exceeded on all metrics
- Over 80% of the portfolio delivered at least mid-to-high single digit or double-digit organic revenue growth driven by good momentum in the sales pipeline
- Strong growth in every region (Americas, Middle East, Europe, Africa and Asia-Pacific), substantially outperforming many underlying markets
- Strong momentum maintained for Sustainability and energy transition solutions across the entire portfolio
- Acquisition of two bolt-on companies further diversifying Consumer Products Services adding annualized revenue of c. EUR 28 million. This includes ANCE, the leading player in Mexico for Electrical and Electronics products (c. EUR 21 million of revenue), announced today
- Good progress towards the achievement of the 2025 CSR ambitions; commitment recognized by several non-financial rating agencies, including a first ranking in the 2023 S&P Global rating (DJSI); mid-term GHG emissions targets approved by the Science Based Targets initiative (SBTi)
2024 Outlook
Leveraging a healthy and growing sales pipeline, high customer demand for ‘new economy services’ and strong underlying market growth, Bureau Veritas expects to deliver for the full year 2024:
- Mid-to-high single-digit organic revenue growth;
- Improvement in adjusted operating margin at constant exchange rates;
- Strong cash flow, with a cash conversion above 90%.
The Group expects H2 organic revenue growth above H1 (with stronger comparables in H1).
Hinda Gharbi, Chief Executive Officer, commented:
“We delivered very strong results in 2023, reflecting our robust business fundamentals, our consistent execution and our customer centricity around the globe. We achieved organic growth of 8.5%, a healthy organic margin of 16.2%, and record earnings per share of EUR 1.27, up over 17% at constant exchange rates.
I would like to warmly thank all our colleagues around the world for their dedication and hard work to deliver this outstanding performance.
I also want to thank our shareholders for their continued support. As a result of our robust cash flow generation and financials, the Board is recommending a dividend increase of 8% compared to last year.
I am convinced that we can take Bureau Veritas to higher levels of performance and achievement. Our portfolio of leading global business lines, strong execution track record and exposure to positive secular trends are key contributors to our current performance and a great foundation for future outperformance.
Specifically, we expect powerful demand for services supporting transition to sustainable development models, evolving buildings integrity needs, growing infrastructure investment and increased spending in low-carbon energy development. Our current pipeline of opportunities in these business areas is a testament to this durable growth dynamic. I look forward to updating the market with our vision and new strategy at our Capital Markets Day on March 20th.
For 2024, we expect Bureau Veritas to deliver another strong year of organic revenue growth, margin expansion4 and strong cash conversion.”
Click here to download the complete Press Release.
About Bureau Veritas
Bureau Veritas is a world leader in laboratory testing, inspection and certification services. Created in 1828, the Group has circa 82,000 employees located in nearly 1,600 offices and laboratories around the globe. Bureau Veritas helps its 400,000 clients improve their performance by offering services and innovative solutions in order to ensure that their assets, products, infrastructure and processes meet standards and regulations in terms of quality, health and safety, environmental protection and social responsibility.
Bureau Veritas is listed on Euronext Paris and belongs to the CAC 40 ESG, CAC Next 20, CAC 40 SBT 1.5, and SBF 120 indices. Compartment A, ISIN code FR 0006174348, stock symbol: BVI.
For more information, visit www.bureauveritas.com, and follow us on Twitter (@bureauveritas) and LinkedIn.
1 Alternative performance indicators are presented, defined and reconciled with IFRS in appendices 6 and 8 of this press release.
2 Ratio of adjusted net financial debt divided by consolidated EBITDA (earnings before interest, tax, depreciation, amortization and provisions), adjusted for any entities acquired over the last 12 months.
3 Proposed dividend, subject to Shareholders’ Meeting approval on June 20, 2024.
4 At constant currency
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240221228025/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
